Padmanee 'Pam' Sharma
InvestorVenture Partner at Catalio Capital Management, LP
Houston, Texas
Writes $100K – $5M checks · typically $1.5M
About
Sharma is a physician-scientist specializing in immunology, immunotherapy, and genitourinary medical oncology, and serves as Co-Director of the Parker Institute for Cancer Immunotherapy at The University of Texas MD Anderson Cancer Center. She earned a BA and MA from Boston University and an MD/PhD from Pennsylvania State University College of Medicine, completing a residency at New York Presbyterian Hospital, Weill Cornell Medical Center, and a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center. She has co-founded several biotechnology companies and served on numerous scientific advisory boards.
Invests in
Biotech
Investments
Board seats
AgilicellApricity HealthJounce Therapeutics (NASDAQ: JNCE)
Per the firm's website.
Colleagues at Catalio Capital Management, LP
Frequently asked questions
- Who is Padmanee 'Pam' Sharma?
- Sharma is a physician-scientist specializing in immunology, immunotherapy, and genitourinary medical oncology, and serves as Co-Director of the Parker Institute for Cancer Immunotherapy at The University of Texas MD Anderson Cancer Center. She earned a BA and MA from Boston University and an MD/PhD from Pennsylvania State University College of Medicine, completing a residency at New York Presbyterian Hospital, Weill Cornell Medical Center, and a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center. She has co-founded several biotechnology companies and served on numerous scientific advisory boards.
- Where does Padmanee 'Pam' Sharma work?
- Padmanee 'Pam' Sharma is Venture Partner at Catalio Capital Management, LP.
- What does Padmanee 'Pam' Sharma invest in?
- Padmanee 'Pam' Sharma invests in Biotech.
- What check size does Padmanee 'Pam' Sharma write?
- Padmanee 'Pam' Sharma typically writes checks of $100K – $5M.
- What boards does Padmanee 'Pam' Sharma sit on?
- Padmanee 'Pam' Sharma holds tracked board seats at Agilicell, Apricity Health, Jounce Therapeutics (NASDAQ: JNCE).